[
  {
    "objectID": "docs/analyses/phind_rnaseq.html",
    "href": "docs/analyses/phind_rnaseq.html",
    "title": "",
    "section": "",
    "text": "PHIND RNA-seq\n\n\n\nnf-core/rna-seq\n\nI used the nf-core/rna-seq pipeline (v3.14.0) to analyse RNA-sequencing data.\nparams yaml\nI used GRCh38 as the reference genome. The QC is reasonable.\nThe pipeline parameters were relatively vanilla. In a larger analysis, there would be a little more optimisation to do.\n\n\n\nTranscript abundance to count matrices\n\nI used the Bioconductor package tximport in R version 4.3.1 to summarise transcript-level estimates (salmon files) into a count matrix. Counts are length scaled transcripts per million (nTPM).\nScript - 01_tximport_DESeq2.R\n\n\n\nOutlier detection and filtering\n\nI filtered all genes with ≤10 normalised TPM.\nAt this step, I also filtered some genes which are related to U2 and are massively over expressed across the board. These were:\n\nENSG00000275616\nENSG00000274062\nENSG00000275219\nENSG00000274862\n\nI performed Generalised PCA on the count matrix, with the package glmpca. I identified samples which were more than 2.5 SD from the mean in either (or both) of the first 2 PCs and removed them.\n\nGCTU_PN0047\nGCTU_PN0052\n\nScript - 02_outliers.R\nI then re-imported the salmon files.\nScript - 03_tximport_DESeq2_filtered.R\n\n\n\nDifferential expression\n\nI used DESeq2 to perform differential expression analysis, based on subphenotype. I used the ‘il6_stnfr1_hco3_poc_alloc’ metadata column to assign samples to a subphenotype. Where this value was missing, I imputed it based on the ‘il6_stnfr1_hco3_elisa_alloc’ column. For sample GCTU_PN0090, I assumed the patient to be hypoinflammatory.\nScript - 04_DE.R\nAt an adjusted P value threshold &lt;0.1, for hyperinflammatory vs. hypoinflammatory, there were:\n\n130 (0.47%) up-regulated genes (LFC &gt;0)\n438 (1.6%) down-regulated genes (LFC &lt;0)\n\nApplying a log2 fold change threshold of &gt; 1.2 or &lt; -1.2, there were:\n\n37 up-regulated genes\n104 down-regulated genes\n\n\nUp-regulated genes (adj P &lt;0.1 and abs(Log2FC) &gt; 1.2)\n\nClick to expand\n\n\n\nGene\nEnsembl ID\nLog2 FC\nadj P value\n\n\n\n\nSPRY2\nENSG00000136158\n2.00\n0.0034\n\n\nMS4A4A\nENSG00000110079\n1.77\n0.0037\n\n\nCTSL\nENSG00000135047\n1.32\n0.0041\n\n\nIGHV3-11\nENSG00000211941\n2.42\n0.0056\n\n\nMCAM\nENSG00000076706\n3.67\n0.0074\n\n\nRASGEF1B\nENSG00000138670\n1.21\n0.0077\n\n\nDNM1\nENSG00000106976\n1.43\n0.0126\n\n\nPCSK9\nENSG00000169174\n2.99\n0.0189\n\n\nADCY6\nENSG00000174233\n1.57\n0.0257\n\n\nSEMA6B\nENSG00000167680\n1.39\n0.0327\n\n\nC1QB\nENSG00000173369\n1.77\n0.0327\n\n\nTNIP3\nENSG00000050730\n1.70\n0.0334\n\n\nROM1\nENSG00000149489\n1.27\n0.0334\n\n\nEMP1\nENSG00000134531\n1.53\n0.0380\n\n\nB4GALT2\nENSG00000117411\n1.35\n0.0385\n\n\nSPRY1\nENSG00000164056\n2.09\n0.0408\n\n\nIL31RA\nENSG00000164509\n1.60\n0.0511\n\n\nRBPMS\nENSG00000157110\n2.90\n0.0517\n\n\nIGHV7-4-1\nENSG00000282122\n3.42\n0.0529\n\n\nC1QC\nENSG00000159189\n1.96\n0.0536\n\n\nIGHV5-51\nENSG00000211966\n1.64\n0.0546\n\n\nC1QA\nENSG00000173372\n1.71\n0.0581\n\n\nLOC100129844\nENSG00000218565\n1.76\n0.0604\n\n\nRAB38\nENSG00000123892\n1.28\n0.0622\n\n\nCKAP2L\nENSG00000169607\n1.25\n0.0633\n\n\nCAVIN1\nENSG00000177469\n1.25\n0.0676\n\n\nFAM20A\nENSG00000108950\n1.28\n0.0695\n\n\nUncategorised\nENSG00000279319\n1.22\n0.0699\n\n\nAS to AKAP8\nENSG00000268189\n1.41\n0.0738\n\n\nSLCO4A1\nENSG00000101187\n1.57\n0.0776\n\n\nAPOBEC3H\nENSG00000100298\n1.38\n0.0782\n\n\nSYNC\nENSG00000162520\n1.63\n0.0788\n\n\nEGR3\nENSG00000179388\n1.51\n0.0788\n\n\nLDHAP4\nENSG00000214110\n1.52\n0.0792\n\n\nCOL4A4\nENSG00000081052\n1.54\n0.0908\n\n\nKIF20A\nENSG00000112984\n1.60\n0.0943\n\n\nSLC12A5-AS1\nENSG00000204044\n1.50\n0.0991\n\n\n\nAS - antisense\n\nDown-regulated genes (adj P &lt;0.1 and abs(Log2FC) &gt; 1.2)\n\nClick to expand\n\n\n\nGene\nEnsembl ID\nLog2 FC\nadj P value\n\n\n\n\nRNA gene\nENSG00000288875\n-1.73\n0.00066\n\n\nAS to LTA4H\nENSG00000257878\n-1.76\n0.00093\n\n\nAS to TUBA1C\nENSG00000258101\n-1.37\n0.00093\n\n\nREM2\nENSG00000139890\n-1.28\n0.00102\n\n\nUncategorised\nENSG00000279884\n-1.37\n0.00103\n\n\nEFCAB12\nENSG00000172771\n-1.32\n0.00256\n\n\nTMEM252\nENSG00000181778\n-1.57\n0.00270\n\n\nAS to GDPD3\nENSG00000275371\n-2.24\n0.00280\n\n\nSDF2 pseudogene\nENSG00000260152\n-1.65\n0.00365\n\n\nAOC3\nENSG00000131471\n-1.20\n0.00428\n\n\nUncategorised\nENSG00000289478\n-1.34\n0.00433\n\n\nCCDC13-AS2\nENSG00000225611\n-1.89\n0.00542\n\n\nGRAMD1C\nENSG00000178075\n-1.76\n0.00664\n\n\nUncategorised\nENSG00000272563\n-1.23\n0.00769\n\n\nUncategorised\nENSG00000226904\n-2.48\n0.00783\n\n\nNHS\nENSG00000188158\n-1.28\n0.00790\n\n\nRERE-AS1\nENSG00000232912\n-1.20\n0.00790\n\n\nUncategorised\nENSG00000289434\n-1.93\n0.01018\n\n\nRCC1 pseudogene\nENSG00000218713\n-1.48\n0.01076\n\n\nLINC02289\nENSG00000258819\n-1.69\n0.01076\n\n\nUncategorised\nENSG00000275898\n-2.35\n0.01241\n\n\nCPEB2-DT\nENSG00000247624\n-1.41\n0.01288\n\n\nYPEL3-DT\nENSG00000250616\n-1.52\n0.01289\n\n\nELAPOR1\nENSG00000116299\n-1.42\n0.01354\n\n\nAS to GPR68\nENSG00000258875\n-1.62\n0.01376\n\n\nUncategorised\nENSG00000288700\n-1.35\n0.01414\n\n\nAS to DPEP2\nENSG00000289618\n-1.22\n0.01419\n\n\nMRPL18 pseudogene\nENSG00000262636\n-1.79\n0.01427\n\n\nTIGD3\nENSG00000173825\n-1.60\n0.01451\n\n\nBICDL2\nENSG00000162069\n-1.92\n0.01504\n\n\nSLC2A3P2\nENSG00000185031\n-1.22\n0.01504\n\n\nC1GALT1P1\nENSG00000257818\n-2.09\n0.01572\n\n\nIFI27\nENSG00000165949\n-2.69\n0.01574\n\n\nUncategorised\nENSG00000237217\n-1.63\n0.01792\n\n\nLINC00222\nENSG00000203801\n-2.01\n0.01918\n\n\nPTPNS pseudogene\nENSG00000234282\n-1.23\n0.01918\n\n\nUncategorised\nENSG00000285966\n-1.83\n0.01918\n\n\nUncategorised\nENSG00000289347\n-1.42\n0.02124\n\n\nAS to NEDD9\nENSG00000290062\n-1.60\n0.02228\n\n\nAS to LTA4H\nENSG00000257715\n-2.62\n0.02348\n\n\nUncategorised\nENSG00000289977\n-1.26\n0.02380\n\n\nLOC101928389\nENSG00000235834\n-1.45\n0.02559\n\n\nNT5DC4\nENSG00000144130\n-1.60\n0.02666\n\n\nAS to GMFG\nENSG00000290031\n-1.27\n0.02671\n\n\nCORIN\nENSG00000145244\n-2.35\n0.02886\n\n\nITPK1-AS1\nENSG00000258730\n-2.51\n0.02958\n\n\nRAPH1\nENSG00000173166\n-1.36\n0.03265\n\n\nAS to MAPL1\nENSG00000289564\n-1.38\n0.03324\n\n\nLINC02555\nENSG00000260943\n-1.68\n0.03342\n\n\nUncategorised\nENSG00000289251\n-1.24\n0.03342\n\n\nCTTNBP2\nENSG00000077063\n-3.48\n0.03790\n\n\nUncategorised\nENSG00000255801\n-1.53\n0.03845\n\n\nSPDYA\nENSG00000163806\n-1.61\n0.03971\n\n\nPFDN1P2\nENSG00000248188\n-1.42\n0.04071\n\n\nUncategorised\nENSG00000286796\n-1.31\n0.04071\n\n\nAS to GDPD3\nENSG00000261367\n-2.22\n0.04239\n\n\nFAM192BP\nENSG00000231841\n-1.93\n0.04294\n\n\nTAF11L2\nENSG00000284373\n-2.31\n0.04322\n\n\nFN1\nENSG00000115414\n-1.90\n0.04402\n\n\nCCT8P1\nENSG00000226015\n-1.57\n0.04587\n\n\nUncategorised\nENSG00000273272\n-1.20\n0.04751\n\n\nTHEM5\nENSG00000196407\n-2.28\n0.04898\n\n\nUncategorised\nENSG00000289573\n-1.22\n0.04899\n\n\nXKR3\nENSG00000172967\n-1.67\n0.04963\n\n\nGLI1\nENSG00000111087\n-2.20\n0.04990\n\n\nRPSAP22\nENSG00000229648\n-1.39\n0.05894\n\n\nAS to ELK3\nENSG00000287454\n-2.13\n0.05998\n\n\nTAS2R62P\nENSG00000234066\n-1.64\n0.06035\n\n\nNRCAM\nENSG00000091129\n-3.06\n0.06055\n\n\nAS to AQP9\nENSG00000289948\n-1.54\n0.06055\n\n\nLLCFC1\nENSG00000165131\n-2.11\n0.06210\n\n\nC7orf25\nENSG00000136197\n-1.24\n0.06338\n\n\nLOC100288146\nENSG00000251473\n-2.14\n0.06338\n\n\nUncategorised\nENSG00000282742\n-1.56\n0.06401\n\n\nLINC01765\nENSG00000233730\n-1.80\n0.06631\n\n\nCHCHD7 pseudogene\nENSG00000260103\n-1.92\n0.06718\n\n\nCTDNEP1P1\nENSG00000241889\n-1.98\n0.06903\n\n\nVSIG1\nENSG00000101842\n-1.65\n0.06995\n\n\nENPP3\nENSG00000154269\n-2.51\n0.06995\n\n\nMPHOSPH10P1\nENSG00000260078\n-1.96\n0.07281\n\n\nNDUFB8P2\nENSG00000270264\n-1.57\n0.07281\n\n\nUncategorised\nENSG00000251093\n-1.22\n0.07541\n\n\nAS to ABCC6\nENSG00000262332\n-2.43\n0.07541\n\n\nAS to MYO1D\nENSG00000266718\n-1.77\n0.07875\n\n\nUncategorised\nENSG00000259959\n-1.33\n0.07896\n\n\nRUFY4\nENSG00000188282\n-1.61\n0.08107\n\n\nLINC00622\nENSG00000260941\n-1.83\n0.08118\n\n\nSPTBN5\nENSG00000137877\n-1.52\n0.08137\n\n\nSRD5A3P1\nENSG00000270929\n-1.85\n0.08150\n\n\nLOC105370152\nENSG00000289381\n-1.28\n0.08397\n\n\nLYPLAL1-DT\nENSG00000228063\n-1.51\n0.08425\n\n\nUncategorised\nENSG00000260337\n-2.36\n0.08480\n\n\nIGSF9B\nENSG00000080854\n-1.32\n0.08508\n\n\nAS to KCNJ6\nENSG00000289538\n-1.41\n0.08931\n\n\nOTX1\nENSG00000115507\n-1.37\n0.09022\n\n\nTAS2R60\nENSG00000185899\n-1.45\n0.09025\n\n\nOverlapping ZNF435\nENSG00000261839\n-1.79\n0.09179\n\n\nAS to SLC5A9\nENSG00000272491\n-1.52\n0.09179\n\n\nLINC00908\nENSG00000266256\n-1.36\n0.09434\n\n\nUncategorised\nENSG00000288737\n-1.32\n0.09468\n\n\nAS to ZFP36L2\nENSG00000287387\n-1.29\n0.09507\n\n\nLINC02723\nENSG00000231680\n-1.36\n0.09548\n\n\nAS to ST6GALNAC2\nENSG00000267078\n-1.54\n0.09641\n\n\nRC3H1-DT\nENSG00000224977\n-1.91\n0.09676\n\n\n\nAS - antisense\n\n\n\n\n\n\nFunctional enrichment\n\nI performed functional enrichment of all significantly differentially expressed genes (adj P &lt;0.1 and abs(Log2FC) &gt; 1.2), against the background of all genes with &gt; 10 nTPM.\nFirst, over representation analysis using GO, KEGG, Reactome, WikiPathways, and the Human Protein Atlas. I used the grprofiler2 package, with ordered queires and a FDR &lt;0.01.\nScript - 05_functional_enrichment.R\n\n\nUp-regulated genesDown-regulated genes\n\n\n\nGO Biological Process\n\nClick to expand\n\n\n\nKEGG\n\nClick to expand\n\n\n\nReactome\n\nClick to expand\n\n\n\nWikiPathways\n\nClick to expand\n\n\n\nHuman Protein Atlas\nNil\n\n\n\nNo significantly enriched pathways\n\n\n\n\n\nProtein-protein interaction\n\nI created a PPI network using STRINGdb and significantly differentially regulated genes (adj P &lt;0.1 and abs(Log2FC) &gt; 1.2). This mapped 59 proteins. There were 22 edges, giving an enrichment P value of 3.35e-05.\nScript - 06_protein_protein_interaction.R\n\nI then MCL clustered this network, identifying 8 clusters.\n\nThe following enrich against Reactome:\n\nCluster 2 - Classical antibody-mediated complement activation\nCluster 3 - RHOB/RHOC/RAC2 GTPase cycle\nCluster 7 - EGFR downregulation\nCluster 8 - Interaction between L1 and Ankyrins\n\n\n\n\nOverlap with existing inflammatory subphenotype RNA-seq studies\n\nNext, I considered the overlap between DEGs in PHIND with DEGs in two other RNA-seq studies:\n\nSarma, A. et al. Hyperinflammatory ARDS is characterized by interferon-stimulated gene expression, t-cell activation, and an altered metatranscriptome in tracheal aspirates. bioRxiv (2022).\nSinha, P et al. Molecular phenotypes of acute respiratory distress syndrome in the ROSE trial have differential outcomes and gene expression patterns that differ at baseline and longitudinally over time. Am. J. Respir. Crit. Care Med. 209(7):816-828 (2024).\n\nScript - 07_gene_overlap.R\nI retrieved hyper vs. hypoinflammatory DEGs from these studies based on the same criteria - adj P value &lt;0.1 and abs(Log2FC) &gt; 1.2.\n\nSarma\n\nSinha day 0\n\nSinha day 2\n\n\n\n\nClustering signatures based on gene embedding\n\nGiven the limited overlap between studies based on gene identity. I embedded the DEGs (gene signatures) from each study using pre-derived functional embeddings:\n\nChehen, H. et al. Drug target prediction through deep learning functional representation of gene signatures. Nat. Commun. 15(1):1853 (2024). https://github.com/chenhcs/FRoGS\n\nEmbeddings - embeddings.csv\nTo create a background, I randomly partitioned the PHIND data using the same proportions of hyper and hypoinflammatory patients, and iterated DE analysis 1000 times. This returned 208 random gene signatures with ≥ 10 genes.\nScript - compute_embeddings.py\n\n\n\nI then formally assessed whether the study derived signatures were more or less similar when compared to the background. I computed the pairwise Euclidean distance between all pairs of study signatures and from each study signature to each random signature.\nI then performed paired t tests and Wilcoxon signed-rank tests - comparing the means of the within-study distances to the study-to-random distances.\n\nPaired t-test results: statistic = -4.52758, p-value = 0.00624\nWilcoxon signed-rank test results: statistic = 0.0, p-value = 0.03125\n\nThe mean within-study distance was 0.28876 vs. 0.45015 from study to random signatures.\nScript - embeddings_similarity.py\n\n\n\nI also calculated an estimate of the effect size using Cohen’s d which was -2.89138, suggesting that the within study distances are smaller than study to random background and that the magnitude of this difference is substantial.\nTo defend against assumptions in the t test and Wilcoxon ranked-sign test, I also conducted a permutation test:\n\nObserved Difference: First, I calculated the actual difference between the mean of within-study distances and the mean of study-to-random distances. This is the observed difference.\nCombining Data: I then combined all the distances (both within-study and study-to-random) into a single pool of data.\nPermutation Process: I randomly shuffled this combined pool of data. After shuffling, we split the data back into two groups of the same sizes as our original groups. I calculated the difference in means between these new, randomly assigned groups. I repeated this 10,000 times.\nComparison: For each permutation, I compared the randomly generated difference to the observed difference. I counted how many times the permuted difference is as extreme as or more extreme than our observed difference.\nP-value Calculation: The p-value is calculated as the proportion of permutations where the permuted difference was as extreme as or more extreme than the observed difference.\n\nThe P value was &lt; 0.0001\nScript - embeddings_cohensd_and_perm.py"
  },
  {
    "objectID": "docs/projects/projectlist.html",
    "href": "docs/projects/projectlist.html",
    "title": "",
    "section": "",
    "text": "Current projects\n\nHere you can view various apps and gizmos I’ve created. Have a play through some of them let me know what you think!\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFroGS embeddings generator \n\n\nStreamlit app to generate FroGS embeddings\n\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "docs/papers/publist.html",
    "href": "docs/papers/publist.html",
    "title": "",
    "section": "",
    "text": "Original articles\n\nGoogle Scholar\nORCID\n\n2024\n\nMillar JE, Clohisey-Hendry S, McMannus M, et. al. \nThe genomic landscape of Acute Respiratory Distress Syndrome: a meta-analysis by information content of genome-wide studies of the host response.\nmedRxiv, 13.234301089.\n\n\n\n\n2023\n\nSwets MC, Kerr S, Scott-Brown J, …, Millar JE, …, Baillie JK.\nEvaluation of pragmatic oxygenation measurement as a proxy for Covid-19 severity.\nNat. Comms., 14:7374.\nhttps://doi.org/10.1038/s41467-023-42205-6\n\n\nMalfertheiner MV, Garrett A, Passmore M, …, Millar JE, …, Fraser JF.\nThe effects of nitric oxide on coagulation and inflammation in ex-vivo models of extracorporeal membrane oxygenation and cardiopulmonary bypass.\nArtif. Organs, 47(10):1581-1591.\nhttps://doi.org/10.1111/aor.14608\n\n\nPairo-Castineira E, Rawlik K, Bretherick AD, …, Millar JE, …, Baillie JK.\nGWAS and meta-analyses identifies 49 genetic variants underlying critical COVID-19.\nNature, 617(7962):764-768.\nhttps://doi.org/10.1038/s41586-023-06034-3\n\n\nSee Hoe LE, Li Bassi G, Wildi K, …, Millar JE, …, Fraser JF.\nDonor heart ischemic time can be extended to 8 hours using hypothermic machine perfusion in sheep.\nJ. Heart Lung Transplant., S1053-2498(23)01819-3.\nhttps://doi.org/10.1016/j.healun.2023.03.020\n\n\n\n\n2022\n\nMillar JE, Boyle AJ, Drake TD, et. al.\nExtracorporeal carbon dioxide removal in acute hypoxaemic respiratory failure: a systematic review, Bayesian meta-analysis, and trial sequential analysis.\nEur. Respir. Rev., 31:220030.\nhttps://doi.org/10.1183/16000617.0030-2022\n\n\nWildi K, Hyslop K, Millar JE, et. al.\nValidation of mRNA markers expressed in human ARDS subgroups in an ovine model of ARDS phenotypes.\nFront. Med., 9:961336.\nhttps://doi.org/10.3389/fmed.2022.961336\n\n\nMillar JE, Neyton L, Seth S, et. al.\nDistinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study.\nSci. Rep., 12, 6843.\nhttps://doi.org/10.1038/s41598-022-08032-30\n\n\nKousathanas A, Pairo-Castineira E, Rawlik K, …, Millar JE, …, Baillie JK.\nWhole genome sequencing reveals host factors underlying critical COVID-19.\nNature, 607(7917):97-103.\nhttps://doi.org/10.1038/s41586-022-04576-6\n\n\nReyes LF, Murthy S, Garcia-Gallo E, …, Millar JE, …, Olliaro PL.\nClinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the ISARIC WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study.\nEur. Respir. J. Open Res., 8(1):00552-2021.\nhttps://doi.org/10.1183/23120541.00552-2021\n\n\nWinslow RL, Zhou J, Windle EF, …, Millar JE, …Green CA.\nSARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating procedures.\nThorax, 77(3):259-267.\nhttps://doi.org/10.1136/thoraxjnl-2021-218035\n\n\n\n\n2021\n\nLi Bassi G, Suen JY, Dalton HJ, …, Millar JE, …, Fraser JF.\nAn appraisal of respiratory system compliance in mechanically ventilated COVID-19 patients.\nCrit. Care, 25: 199.\nhttps://doi.org/10.1186/s13054-021-03518-4\n\n\nMcNamee JJ, Gillies MA, Barrett NA, …, Millar JE, …, McAuley DF.\nEffect of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal vs standard care ventilation on 90-day mortality in patients with acute hypoxemic respiratory failure: the REST randomized trial.\nJAMA, 326(11):1013-1023.\nhttps://doi.org/10.1001/jama.2021.13374\n\nDolby HW, Potey P, Wilder-Smith AB, …, Millar JE, …, Russell CD.\nHistological evidence of pulmonary microthrombosis and vasculitis in life-threatening respiratory virus disease.\nOpen Forum Inf. Dis., 8(2):ofaa640.\nhttps://doi.org/10.1093/ofid/ofaa640\n\n\nKi KK, Millar JE, Langguth D, et. al.\nCurrent understanding of leukocyte phenotypic and functional modulation during extracorporeal membrane oxygenation: a narrative review.\nFront. Immunol., 11:600684.\nhttps://doi.org/10.3389/fimmu.2020.600684\n\n\nFulton R, Millar JE, Merza M, et. al.\nProphylactic postoperative high flow nasal oxygen versus conventional therapy in obese patients undergoing bariatric surgery (OXYBAR): a pilot randomised controlled trial.\nObes. Surg., 31(11):47994807.\nhttps://doi.org/10.1007/s11695-021-05644-y\n\nMillar JE, Wildi K,Bartnikowski N,et. al.\nCharacterizing preclinical sub-phenotypic models of acute respiratory distress syndrome: an experimental ovine study.\nPhysiol. Rep., 9(19):e15048.\nhttps://doi.org/10.14814/phy2.15048\n\n\nSee Hoe LE, Wildi K, Obonyo NG, …, Millar JE, …, Fraser JF.\nA clinically relevant sheep model of orthotopic heart transplantation 24 h after donor brainstem death.\nIntensive Care Med. Exp., 9(1):60.\nhttps://doi.org/10.1186/s40635-021-00425-4\n\n\nPairo-Castineira E, Clohisey S, Klaric L, …, Millar JE, …, Baillie JK.\nGenetic mechanisms of critical illness in COVID-19.\nNature, 591(7848):92-98.\nhttps://doi.org/10.1038/s41586-020-03065-y\n\n\nCOVID-19 Host Genetics Initiative.\nMapping the human genetic architecture of COVID-19.\nNature, 600(7889):472-477.\nhttps://doi.org/10.1038/s41586-021-03767-x\n\n\n\n\n2020\n\nParkinson N, Rodgers N, Fourman MH, …, Millar JE, …, Clohisey S.\nDynamic data-driven meta-analysis for prioritisation of host genes implicated in COVID-19.\nSci. Rep., 10(1):22303.\nhttps://doi.org/10.1038/s41598-020-79033-3\n\n\nSoulsby CR, Hutchison, Gardner J, …, Millar JE.\nSocio-economic deprivation and the risk of death after ICU admission with COVID-19: The poor relation.\nJ. Intensive Care Soc.,\nhttps://doi.org/10.1177/1751143720978855\n\n\nGorman E, Millar JE, McAuley D, et. al.\nMesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.\nExpert Rev. Respir. Med., 15(3):301-324.\nhttps://doi.org/10.1080/17476348.2021.1848555\n\nBurton F, Lowe DJ, Millar JE, et. al.\nPropofol target-controlled infusion in emergency department sedation (Peo-TEDS): a multicentre, single-arm feasibility study.\nEmerg. Med. J., 38(3):205–210.\nhttps://doi.org/10.1136/emermed-2020-209686\n\n\nLi Bassi G, Suen JY, Barnett AG, …, Millar J, …, Fraser JF.\nDesign and rationale of the COVID-19 Critical Care Consortium international, multicentre, observational study.\nBMJ Open, 10(12):e041417.\nhttps://doi.org/10.1136/bmjopen-2020-041417\n\n\nHeinser S, Rozencwajg S, Suen JY, …, Millar JE.\nHeart failure supported by veno-arterial extracorporeal membrane oxygenation (ECMO): a systematic review of pre-clinical models.\nIntensive Care Med. Exp., 8:16.\nhttps://doi.org/10.1186/s40635-020-00303-5\n\n\nMalfertheiner MV, Koch C, Fisser C, Millar JE, et. al.\nIncidence of early intra-cranial bleeding and ischaemia in adult veno-arterial extracorporeal membrane oxygenation and extracorporeal cardiopulmonary resuscitation patients: a retrospective analysis of risk factors.\nPerfusion, 35(1_suppl):8-17.\nhttps://doi.org/10.1177/0267659120907438\n\n\nMalfertheiner MV, Broman LM, Vercaemst L, …, Millar JE, …, Fraser JF.\nEx vivo models for research in extracorporeal membrane oxygenation: a systematic review of the literature.\nPerfusion, 35(1_suppl):38-49.\nhttps://doi.org/10.1177/0267659120907439\n\n\nMillar JE, Bartnikowski N, Passmore MR, et. al.\nCombined mesenchymal stromal cell therapy and ECMO in ARDS: a randomised controlled trial in sheep. Am. J. Respir. Crit. Care Med., 202(3):383-392.\nhttps://doi.org/10.1164/rccm.201911-2143OC\n\n\nSee Hoe LE, Wells MA, Bartnikowski N, …, Millar JE, …, Fraser JF.\nHeart Transplantation From Brain Dead Donors: A Systematic Review of Animal Models.\nTransplantation, 104(11):2272-2289.\nhttps://doi.org/10.1097/TP.0000000000003217\n\n\nBurton FM, Lowe DJ, Millar JE, et. al.\nEffect of target-controlled propofol infusion to reduce the incidence of adverse events for procedural sedation in the emergency department: a systematic review.\nEur. J. Emerg. Med., 27(4):253259.\nhttps://doi.org/10.1097/MEJ.0000000000000655\n\n\n\n2019\n\nKi KK, Passmore MR, Chan CHH, …, Millar JE, …, Suen JY.\nLow flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuit.\nIntensive Care Med. Exp., 7:51.\nhttps://doi.org/10.1186/s40635-019-0264-z\n\n\nMillar JE, Bartnikowski N, von Bahr V, et. al.\nExtracorporeal membrane oxygenation (ECMO) and the acute respiratory distress syndrome (ARDS): a systematic review of pre-clinical models.\nIntensive Care Med. Exp., 7(1):18.\nhttps://doi.org/10.1186/s40635-019-0232-7\n\n\nvon Bahr, Millar JE, Malfertheiner MV, et. al.\nMesenchymal stem cells may ameliorate inflammation in an ex-vivo model of extracorporeal membrane oxygenation.\nPerfusion, 34(1suppl):15-21.\nhttps://doi.org/10.1177/0267659119830857\n\nvon Bahr V, Kalzen H, Frenckner B, …, Millar JE, …, Holzgraefe B.\nLong-term pulmonary function and quality of life in adults after extracorporeal membrane oxygenation for respiratory failure.\nPerfusion, 34(1suppl):49-57.\nhttps://doi.org/10.1177/0267659119830244\n\nObonyo NG, Byrne L, Tung JP, …, Millar JE, …, Fraser JF.\nPre-clinical study protocol: Blood transfusion in endotoxaemic shock.\nMethods X, 6:1124–1132.\nhttps://doi.org/10.1016/j.mex.2019.05.005\n\n\nBurton FM, Lowe DJ, Millar J, et. al.\nA study protocol for a feasibility study: Propofol Target-Controlled Infusion in Emergency Department Sedation (PRoTEDS) – a multicentre feasibility study protocol.\nPilot Feasibility Stud., 5:27.\nhttps://doi.org/10.1186/s40814-019-0412-y\n\n\nFanning JP, SeeHoe LE, Passmore MR, …, Millar JE, …, Fraser JF.\nNeuron-Specific Enolase and matrix metalloproteinase 9 signal perioperative silent brain infarction during or after transcatheter aortic valve implantation.\nAm. J. Cardiol., 123(3):434-439.\nhttps://doi.org/10.1016/j.amjcard.2018.10.022\n\nMillar JE, von Bahr V, Malfertheiner MV, et. al.\nAdministration of mesenchymal stem cells during ECMO results in a rapid decline in oxygenator performance.\nThorax, 74(2):194-196.\nhttp://dx.doi.org/10.1136/thoraxjnl-2017-211439\n\n\n\n\n2018\n\nFulton R, Millar JE, Merza M, et. al.\nHigh flow nasal oxygen after bariatric (OXYBAR), prophylactic post-operative high flow nasal oxygen versus conventional oxygen therapy in obese patients undergoing bariatric surgery: a study protocol for a randomised controlled pilot trial.\nTrials, 19(1):402.\nhttp://dx.doi.org/10.1007/s11695-021-05644-y\n\nFanning JP, See Hoe LE, Passmore MR, …, Millar JE, …, Fraser JF.\nDifferential immunological profiles herald magnetic resonance imaging-defined perioperative cerebral infarction.\nTher. Adv. Neurol. Dis., 11:1756286418759493.\nhttp://dx.doi.org/10.1177/1756286418759493\n\n\n\n\n2017\n\nMalfertheiner MV, Pimenta LP, von Bahr V, Millar JE, et. al.\nAcquired von Willebrand syndrome in respiratory extracorporeal life support: a systematic review of the literature.\nCrit. Care Resusc., 19(Suppl 1):45-52.\nhttps://pubmed.ncbi.nlm.nih.gov/29084501/\n\n\n\n2016\n\nMillar JE, Fanning JP, McDonald CI, et. al.\nThe inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology.\nCrit. Care, 20:387.\nhttps://doi.org/10.1186/s13054-016-1570-4\n\n\nDevaney J, Smyth R, Lutton S, …, Millar JE.\nThe soda dipstick: A convenient and cost-effective means of identifying the sugar content of soft drinks.\nJ. Diabetes, 8(6):877-878.\nhttps://doi.org/10.1111/1753-0407.12431\n\nLowe DJ, Millar JE, Dignon N, Ireland A.\nTop 10 lessons from the Glasgow major incidents.\nEmerg. Med. J., 33(8):596-7.\nhttps://doi.org/10.1136/emermed-2015-205626\n\n\n\n2014\n\nFitzgerald M, Millar J, Blackwood B, et. al.\nExtracorporeal carbon dioxide removal for patients with acute respiratory failure secondary to the Acute Respiratory Distress Syndrome: a systematic review.\nCrit. Care, 18(3):222.\nhttps://doi.org/10.1186/cc13875\n\n\nMillar J, Lutton S, O’Connor P.\nThe use of high flow nasal oxygen in the management of hypercarbic respiratory failure.\nTher. Adv. Respir. Dis., 8(2):63-4.\nhttps://doi.org/10.1177/1753465814521890\n\n\n\n\n\nEditorials\n\n\n\n2024\n\nMillar JE, Docherty AB.\nIt ain’t what you do (it’s the way that you do it): modulating the host response in sepsis.\nAnaesthesia, Online ahead of print.\nhttps://doi.org/10.1111/anae.16263\n\n\n\n\n2023\n\nMillar JE, O’Kane CM.\nMesenchymal stromal cells and ARDS: more questions than answers.\nAm. J. Respir. Crit. Care Med., 208(12):1257-1259.\nhttps://doi.org/10.1164/rccm.202310-1847ED\n\n\nMillar JE, McAuley DF, Marini JJ.\nDriving pressure - what’s the harm?\nCrit. Care Med., 51(7): 967-970.\nhttps://doi.org/10.1097/CCM.0000000000005874\n\n\n\n\n2020\n\nRussell CD, Millar JE, Baillie JK.\nClinical Evidence Does Not Support Corticosteroid Treatment for 2019-nCoV Lung Injury.\nLancet, 395(10223): 473–475.\nhttps://doi.org/10.1016/S0140-6736(20)30317-2\n\n\nMillar JE, Busse R, Fraser JF, et. al.\nApples and oranges: international comparisons of COVID-19 observational studies in ICUs.\nLancet Respir. Med., 8(10):952–953.\nhttps://doi.org/10.1016/S2213-2600(20)30368-4\n\n\n\n\n2015\n\nMillar JE, Fraser JF, McAuley DF.\nMesenchymal stromal cells and the acute respiratory distress syndrome (ARDS): challenges for clinical application.\nThorax, 70(7):611-2.\nhttp://dx.doi.org/10.1136/thoraxjnl-2015-207121\n\n\n\n\n\nLetters\n\n\n\n2016\n\nMillar JE, Lutton S, McLaughlin R.\nNeed for a systematic audit of trauma care in Northern Ireland.\nBMJ, 353:i2025.\nhttp://dx.doi.org/10.1136/bmj.i2025\n\n\n\n\nBook chapters\n\n\n\n2022\n\nHartley EL, Millar JE, Fraser JF.\nThe unholy blood: biomaterial interaction in extracorporeal circulation. Extracorporeal Membrane Oxygenation: An interdisciplinary problem-based learning approach.\nOxford University Press.\nhttps://doi.org/10.1093/med/9780197521304.003.0012\n\n\n\n2017\n\nMillar JE, Gregory S, Stevens M, Fraser JF, Bartlett B.\nPast, Present, and Future. Mechanical Circulatory and Respiratory Support.\nAcademic Press (Elsevier).\nhttps://doi.org/10.1016/B978-0-12-810491-0.00025-4"
  },
  {
    "objectID": "docs/home/index.html",
    "href": "docs/home/index.html",
    "title": "Johnny Millar",
    "section": "",
    "text": "Senior Clinical Research Fellow & Honorary Consultant in Intensive Care Medicine\nThe University of Edinburgh and the Queen Elizabeth University Hospital, Glasgow\n \n  \n   \n  \n    \n     Twitter\n  \n  \n    \n     GitHub\n  \n  \n    \n     Email\n  \n\n\n\n\nMy research interests include computational biology applied to the lung, the integration of deep-learning and clinical trials, and the functional genomics of ARDS.\nI completed my PhD with Prof John Fraser and Prof Danny McAuley, studying the role of mesenchymal stem cells and ECMO in ARDS.\nSince moving to Edinburgh in 2020, I have worked with Prof Kenneth Baillie at the Baillie-Gifford Pandemic Science Hub, Institute of Regeneration & Repair.\nI have contributed to the Genetics of Mortality in Critical Care (GenOMICC) study and am working to develop in-silico and in-vitro platforms to better understand the functional genomics of ARDS and to discover novel treatments."
  },
  {
    "objectID": "docs/contact/contact.html",
    "href": "docs/contact/contact.html",
    "title": "",
    "section": "",
    "text": "Baillie-Gifford Pandemic Science Hub\n\nInstitute for Regeneration & Repair\n5 Little France Drive\nEdinburgh\nEH16 4UU\nUnited Kingdom\n +44 (0)131 651 9514\n\n\n\n\n\n\n\n\n\n\n\nThe Roslin Institute\n\nBaillie Lab\nThe Roslin Institute\nEaster Bush Campus\nMidlothian\nEH25 9RG\n +44 (0)131 651 9100"
  },
  {
    "objectID": "docs/projects/FroGS_generator/embeddings.html",
    "href": "docs/projects/FroGS_generator/embeddings.html",
    "title": "",
    "section": "",
    "text": "FroGS embeddings generator \n\n\nThe app generates embeddings using the methods developed in:\nChen, H., King, F.J., Zhou, B. et al. Drug target prediction through deep learning functional representation of gene signatures. Nature Commun. 15, 1853 (2024). https://doi.org/10.1038/s41467-024-46089-y\n\n\nInstructions\n\nUpload the GO embedding file (CSV format).\nUpload the ARCHS4 embedding file (CSV format).\nUpload your gene signatures text file (TXT format).\nClick the “Process Files” button to generate embeddings.\nOnce processing is complete, a download button will appear.\nClick the “Download Embeddings CSV” button to download the generated embeddings file.\n\n\n\nImportant Notes\n\nThe gene signatures file should be a text file where each line represents a gene signature.\nEach line should start with the signature name, followed by a comma, and then a comma-separated list of genes.\nEnsure that the genes in your list match the gene identifiers used in the embedding files (i.e., NCBI gene IDs).\nThe embedding files should be in CSV format with gene IDs in the first column and embedding values in the subsequent columns.\n\nPrecomputed GO embeddings\nPrecomputed ARCHS4 embeddings"
  },
  {
    "objectID": "docs/software/softlist.html",
    "href": "docs/software/softlist.html",
    "title": "",
    "section": "",
    "text": "R packages\n\n\n\n ARDSMAICR\n\n\n\n\n\n\n\nThe ARDSMAICR package contains the results of a meta-analysis by information content (MAIC) of genome-wide studies of the host response to acute respiratory distress syndrome (ARDS). These data are accompanied by a range of helper functions useful for analysis.\nDocumentation\n\n\n\n\nPython\n\n\n\n PubMed CLI\n\n \nA Python script that allows you to search PubMed for publications based on a specific query term and a specified number of days back. The script utilizes the Biopython library to interact with the PubMed database.\nFeatures:\n\nSearch PubMed for recent publications using a specific query term\nSpecify the number of days back to search\nFetch article details including title, authors, journal, publication date, PubMed ID, and DOI URL\nView abstracts of selected articles\nOpen article URLs in default browser\nOption to output the results to a CSV file\n\n\n\n\n\nWebsites\n\n\n\n ARDS Genomics website\n\n\n\n\n\n\n\n\n\n PANTHER intervention selection website\n\n\n\n\n\n\n\n\n\n New Global ARDS Definition website\n\n\n\n\n\n\n\n\nData\n\n\n\n Combined Mesenchymal Stromal Cell Therapy and Extracorporeal Membrane Oxygenation in Acute Respiratory Distress Syndrome. A Randomized Controlled Trial in Sheep\n\nPhysiological and biochemical data presented in https://doi.org/10.1164/rccm.201911-2143OC\n\n\n\n Characterizing pre-clinical sub-phenotypic models of acute respiratory distress syndrome: An experimental ovine study\n\nData and code to reproduce the analysis presented in https://doi.org/10.14814/phy2.15048"
  }
]